Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2009 Feb 3;20(4):320–326. doi: 10.1002/clc.4960200404

The design of the mortality assessment in congestive heart failure trial (MACH‐1, Mibefradil)

T Barry Levine 1,✉
PMCID: PMC6656093  PMID: 9098588

Abstract

Background: Despite the advances in therapy for heart failure with the use of angiotensin‐converting enzyme inhibitors, heart failure remains a major medical problem, impacting on well‐being and survival.

Hypothesis: Mibefradil is a member of new class of agents that, due to its unique mechanism of action and pharmacologic and physiologic profile, may offer a significant advance in the treatment of heart failure. Mibefradil is a nonvoltage‐regulated T‐channel calcium blocker that differs from all the other currently available L‐channel calcium blockers. The drug is a potent peripheral and coronary vasodilator, with no clinical negative inotropic activity. Furthermore, because of its long half‐life, it can be given once a day and appears to be free of the common side effects seen with other calcium‐channel blockers. The trial was designed to investigate whether the addition of mibefradil to standard therapy for heart failure will reduce mortality in patients with symptomatic heart failure.

Methods: This manuscript describes the design, organization, and status of MACH‐1 (Mortality Assessment in Congestive Heart Failure), a double‐blind, placebo‐controlled study. It is to be a 2,400‐patient international trial assessing the ability of mibefradil to impact upon survival and symptoms of heart failure in patients who are in NYHA classes II–IV and who were already treated with standard therapy.

Keywords: T‐channel calcium blocker, mibefradil, heart failure, survival

Full Text

The Full Text of this article is available as a PDF (740.5 KB).

References

  • 1. U.S. Dept of Health and Human Services. NHLBI report of the task force on research in heart failure. PHS‐NIH 1994; Springfield, Va. 22161.
  • 2. Schocken DD, Arrieta MI, Leaverton PE: Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol 1992; 20: 301–306. [DOI] [PubMed] [Google Scholar]
  • 3. McKee PA, Castelli WP, McNamara PM, Kannel WB: The natural history of congestive heart failure: The Framingham Study. N Engl J Med 1971; 285: 1440–1446. [DOI] [PubMed] [Google Scholar]
  • 4. CONSENSUS Trial Study Group : Effects of enalapril on mortality in severe congestive heart failure: Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Eng J Med 1987; 316: 1429–1435. [DOI] [PubMed] [Google Scholar]
  • 5. Cohn JN, Johnson G, Ziesche S, Fletcher RD, Doherty JU, Hughes CV, Carson P, Contion G, Shabetai R, Haakenson C: A comparison of enalapril with hydralazine‐isosorbide dinitrate in the treatment of chronic congestive heart failure. N Eng J Med 1991; 325: 303–310. [DOI] [PubMed] [Google Scholar]
  • 6. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford JD, Wertheimer JH, Hawkins CM, on behalf of the SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial. N Engl J Med 1992; 327: 669–677. [DOI] [PubMed] [Google Scholar]
  • 7. Acute Infarction Ramipril Efficacy (AIRE) Study Investigators : Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–828. [PubMed] [Google Scholar]
  • 8. SOLVD Investigators : Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691. [DOI] [PubMed] [Google Scholar]
  • 9. SOLVD Investigators : Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Eng J Med 1991; 325: 293–302. [DOI] [PubMed] [Google Scholar]
  • 10. Clozel JP, Osterrieder W, Kleinbloesem CH, Welker HA, Schlapp B, Tudor R, Hefti F, Schmitt R, Egers H: Ro 40–5967: A new nondihydropyridine calcium antagonist. Cardiovasc Drug Rev 1991; 9: 4–17. [Google Scholar]
  • 11. Mishra SK, Hermsmeyer K: Selective inhibition of T‐type Ca2+ channel by Ro 40–5967. Circulation Res 1994; 75: 144–148. [DOI] [PubMed] [Google Scholar]
  • 12. Clozel JP, Veniant M, Osterrieder W: The structurally novel Ca2+ channel blocker Ro 40–5967, which binds to the [3H] desmeth‐oxyverapamil receptor, is devoid of the negative inotropic effects of verapamil in normal and failing rat hearts. Cardiovasc Drugs Ther 1990; 4: 731–736. [DOI] [PubMed] [Google Scholar]
  • 13. Veniant M, Clozel JP, Wolfgang R: Ro 40–5967, in contrast to diltiazem, does not reduce left ventricular contractility in rats with chronic myocardial infarction. J Cardiovasc Pharmacol 1991; 17: 272–284. [DOI] [PubMed] [Google Scholar]
  • 14. Bakx LM, van der Wall EE, Braun S, Emanuelsson H, Bruschke AVG, Kobrin I: Effects of the new calcium antagonist mibefradil (Ro 40–5967) on exercise duration in patients with chronic stable angina pectoris: A multicenter, placebo‐controlled study. Am Heart J 1995; 130: 748–757. [DOI] [PubMed] [Google Scholar]
  • 15. Braun S, van der Wall EE, Emanuelsson H, Kobrin I: Effects of a new calcium antagonist, mibefradil (Ro‐40–5967), on silent ischemia in patients with chronic angina pectoris: A multicenter placebo‐controlled study. J Am Coll Cardiol 27: 317–322. [DOI] [PubMed] [Google Scholar]
  • 16. Rector TS, Cohn JN: Assessment of patient outcome with the Minnesota Living with Heart Failure questionnaire: Reliability and validity during a randomized, double‐blind, placebo‐controlled trial of pimobendan. Am Heart J 1992; 124: 1017–1025. [DOI] [PubMed] [Google Scholar]
  • 17. Lan S, DeMets DL: Discrete sequential boundaries for clinical trials. Biometrica 1983; 70: 659–663. [Google Scholar]
  • 18. Katz AM: Calcium channel diversity in the cardiovascular system. J Am Coll Cardiol 1996; 28: 522–529. [DOI] [PubMed] [Google Scholar]
  • 19. Bkaily G, Sculptoreau A, Jacques D, Economos D, Mernard D: Apamin, a highly potent fetal L‐type Ca2+ current blocker in single heart cells. Am J Physiol 1992; 262: 463–471. [DOI] [PubMed] [Google Scholar]
  • 20. Balke CW, Rose WC, Marban E, Wier WG: Macroscopic and unitary properties of physiological ion flux through T‐type Ca2+ channels in guinea pig hearts. J Physiol (Lond) 1992; 546: 247–265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Nuss HB, Houser SR: T‐type Ca2+ current is expressed in hypertrophied adult feline left ventricular myocytes. Circ Res 1993; 73: 777–782. [DOI] [PubMed] [Google Scholar]
  • 22. Sen L, Smith TW: T‐type Ca2+ channels are abnormal in genetically determined cardiomyopathic hamster hearts. Circ Res 1994; 75: 149–155. [DOI] [PubMed] [Google Scholar]
  • 23. Xu X, Best PM: Increase in T‐type calcium current in atrial myocytes from adult rats with growth hormone‐secreting tumors. Proc Natl Acad Sci USA 1990; 87: 4655–4659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Wang Z, Estacion M, Mordan LJ: Ca2+ influx via T‐type channels modulates PDGF‐induced replication of mouse fibroblasts. Am J Physiol 1993; 265: C1239–1246. [DOI] [PubMed] [Google Scholar]
  • 25. Furukawa T, Ito H, Niita J, Tsujino M, Adachi S, Hiroe M, Marumo F, Sawanobori T, Hiraoka M: Endothelin‐1 enhances calcium entry through T‐type calcium channels in cultured neonatal rat ventricular myocytes. Circ Res 1992; 71: 1242–1253. [DOI] [PubMed] [Google Scholar]
  • 26. McCarthy RT, Isales C, Rasmussen H: T‐type calcium channels in adrenal glomerulosa cells: GTP‐dependent modulation by angiotensin II. Proc Natl Acad Sci USA 1993; 90: 3260–3264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Hirsch AT, Talsness CE, Schunkert H, Paul M, Dzau VI: Tissue‐specific activation of cardiac angiotensin converting enzyme in experimental heart failure. Circ Res 1991; 69: 475–482. [DOI] [PubMed] [Google Scholar]
  • 28. Colucci WS: Myocardial endothelin: Does it play a role in myocardial failure? Circulation 1996; 93: 1069–1072. [DOI] [PubMed] [Google Scholar]
  • 29. Schmitt R, Clozel J‐P, Iberg N, Buhler FR: Mibefradil prevents neointima formation after vascular injury in rats. Possible role of the blockade of the T‐type voltage‐operated calcium channel. Arterioscl Thromb Vasc Biol 1995; 15: 1161–1165. [DOI] [PubMed] [Google Scholar]
  • 30. Figulla HR, Gietzen F, Zeymer U, Raiber M, Hegselmann J, Soballa R, Hilgers R, for the DiDi Study Group : Diltiazem improves cardiac function and exercise capacity in patients with idiopathic dilated cardiomyopathy. Circulation 1996; 94: 346–352. [DOI] [PubMed] [Google Scholar]
  • 31. Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson PE, Belkin RN, Miller AB, Beuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL, for the Prospective Randomized Amlodipine Survival Evaluation Study Group : Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107–1114. [DOI] [PubMed] [Google Scholar]
  • 32. Packer M: Calcium channel blockers in chronic heart failure: The risks of “physiologically rational” therapy. Circulation 1990; 82: 2254–2257. [DOI] [PubMed] [Google Scholar]
  • 33. Cohn JN, Ziesche SM, Loss LE, Anderson GF, V‐HeFT Study Group : Effect of felodipine on short‐term exercise and neurohormone and long‐term mortality in heart failure: Results of V‐HeFT III. Circulation 1995; 92 (suppl I): I–143. [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES